Literature DB >> 10472557

Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study.

G J Kaspers1, C M Zwaan, A J Veerman, M G Rots, R Pieters, P Bucsky, M Domula, U Göbel, N Graf, W Havers, N Jorch, K Kabisch, H J Spaar, J Ritter, U Creutzig.   

Abstract

Cellular drug resistance is one of the main causes of the frequent ultimate failure of chemotherapy in childhood acute myeloid leukemia (AML). We here summarize the results of a literature review on in vitro drug resistance in childhood AML, focusing on studies using so-called cell culture assays. We also briefly describe some results of an ongoing collaborative study between the Research Laboratory of Pediatric Oncology in Amsterdam (University Hospital Vrije Universiteit) and the German BFM-AML Group. In general, the literature and our preliminary data on in vitro cellular drug resistance in AML are promising in terms of clinical relevance. Cell biological features and clinical response to chemotherapy are related to in vitro drug resistance. However, a large study including multivariate analysis is required to more firmly establish the clinical value of cellular drug resistance testing in childhood AML, and the collaborative study will therefore be continued. Possible applications of cell culture assays include risk-group stratification, rational improvements of current treatment protocols for subgroups of patients based on specific drug resistance profiles, individualised tailored therapy, the study of cross-resistance patterns between drugs, the study of possibilities to modulate or circumvent drug resistance, the study of drug interactions, selection of patients for clinical phase II studies and drug screening.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472557     DOI: 10.1055/s-2008-1043795

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  6 in total

1.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.

Authors:  Henry Ogbomo; Martin Michaelis; Denise Klassert; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

3.  The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Authors:  I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

4.  Gene expression profiles associated with pediatric relapsed AML.

Authors:  Costa Bachas; Gerrit Jan Schuurhuis; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Monique L den Boer; Eveline S J M de Bont; Zinia J Kwidama; Dirk Reinhardt; Ursula Creutzig; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

5.  Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase.

Authors:  Salvatore Nicola Bertuccio; Salvatore Serravalle; Annalisa Astolfi; Annalisa Lonetti; Valentina Indio; Anna Leszl; Andrea Pession; Fraia Melchionda
Journal:  Oncotarget       Date:  2017-06-19

6.  Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia.

Authors:  Limei Wu; Srinivas Chatla; Qiqi Lin; Fabliha Ahmed Chowdhury; Werner Geldenhuys; Wei Du
Journal:  Nat Commun       Date:  2021-11-26       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.